Amyloidosis

Metabolic·MeSH: Immunoglobulin Light-chain Amyloidosis

Prevalence

5.0 / 100K

31 drugs in development·19 companies·9 clinical trials

Drug Pipeline by Phase

Approved(8)

Drug	Company
Amvuttra	Royalty Pharma plc (RPRX)
AMVUTTRA	ALNYLAM PHARMACEUTICALS, INC. (ALNY)
Attruby / Beyonttra (acoramidis)	BridgeBio Pharma, Inc. (BBIO)
ONPATTRO	ALNYLAM PHARMACEUTICALS, INC. (ALNY)
supplemental new drug	ALNYLAM PHARMACEUTICALS, INC. (ALNY)
tegsedi	AKCEA THERAPEUTICS, INC. (AKCA)
Tegsedi	PTC THERAPEUTICS, INC. (PTCT)
wainua	ASTRAZENECA PLC (AZN)

Phase 3(10)

Drug	Company
acoramidis	Eidos Therapeutics, Inc. (EIDX)
acoramidis (AG10)	BridgeBio Pharma, Inc. (BBIO)
Birtamimab	PROTHENA CORP PUBLIC LTD CO (PRTA)
cael-101	ALEXION PHARMACEUTICALS, INC. (ALXN)
cael-101	Fortress Biotech Inc. (FBIO)
CAEL-101	ARS Pharmaceuticals, Inc. (SPRY)
ixazomib	X4 Pharmaceuticals, Inc (XFOR)
Nucresiran	ALNYLAM PHARMACEUTICALS, INC. (ALNY)
Patisiran	ALNYLAM PHARMACEUTICALS, INC. (ALNY)
Vutrisiran	ALNYLAM PHARMACEUTICALS, INC. (ALNY)

Phase 2(2)

Drug	Company
Daratumumab	FATE THERAPEUTICS INC (FATE)
NNC6019	PROTHENA CORP PUBLIC LTD CO (PRTA)

Phase 1(5)

Drug	Company
ALN-TTRSC04	ALNYLAM PHARMACEUTICALS, INC. (ALNY)
Isatuximab	Merus N.V. (MRUS)
Ixazomib	FATE THERAPEUTICS INC (FATE)
NTLA-2001	Intellia Therapeutics, Inc. (NTLA)
nxc-201	Immix Biopharma, Inc. (IMMX)

Preclinical(1)

Drug	Company
ag10	ALEXION PHARMACEUTICALS, INC. (ALXN)

Unknown(1)

Drug	Company
inotersen	AKCEA THERAPEUTICS, INC. (AKCA)

Phase 1/Phase 2(2)

Drug	Company
azd0120	ALEXION PHARMACEUTICALS, INC. (ALXN)
nxc-201 car-t	Axcella Health Inc. (AXLA)

Phase 4(2)

Drug	Company
Isatuximab	Filana Therapeutics Inc. (FLNA)
ixazomib	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)

BioSniper tracks 31 drugs in development for Amyloidosis across 19 companies.

There are 9 clinical trials targeting Amyloidosis tracked by BioSniper.

The estimated prevalence of Amyloidosis is approximately 5.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.